Led · Equity · May 2026

Cellogen Therapeutics is an Indian biotech founded in 2021 that focuses on developing cell and gene therapies using Chimeric Antigen Receptor T‑cell (CAR‑T) technology. Its lead product is a bispecific, dual‑antigen CAR‑T therapy designed to target two cancer markers to potentially reduce relapse risk. The company operates a GMP‑compliant manufacturing facility in Noida with in‑house CAR design and lentiviral vector manufacturing capabilities and has been granted a patent for its CAR‑T platform. Cellogen says it uses AI‑driven platforms in its design and development processes and is developing early‑stage programmes for beta thalassemia and sickle cell disease. It is preparing for Phase I human clinical trials in collaboration with Christian Medical College Vellore, subject to regulatory approvals. The company recently raised Rs 20 crore from Kotak Alts and previously sold a 5.38% stake to Natco Pharma for a little over Rs 15 crore.

Led · Series A · Feb 2026

Founded in 2020 by Sachin and Shweta Darbarwar, Hyderabad-based ZeroHarm Sciences produces plant-derived health supplements using proprietary nano-formulation technology that converts nutrients into nano-sized particles for higher bioavailability and controlled release at lower dosages. The company positions itself as India’s first “Trust over Promise” health platform, pledging to demonstrate supplement efficacy through quantifiable consumer health outcomes. ZeroHarm fully controls its supply chain, sourcing medicinal plants through a network of more than 10,000 farmers across Northeast India and the Himalayas. It holds patents covering turmeric phytochemicals, iron-folic acid blends, carotenoid eye-health compounds, and synbiotic gut-health compositions. The portfolio spans 60+ SKUs addressing diabetes, heart health, joint care, immunity, gut health, oncology support, women’s wellness, and performance nutrition, and products are sold via its own site, Amazon, Flipkart, and quick-commerce channels. To date, the brand has served over 300,000 customers. Future plans include aggressive national brand building, scaling R&D and manufacturing, and expanding sales into the USA, UK, and Middle Eastern markets.

Led · Equity · May 2024

Biorad Medisys Private Ltd is a medical device company that supplies medical consumables, implants and equipment across several segments. The company received a ₹400-crore investment from Kotak Strategic Situations India Fund II. It will use the funds to set up a new manufacturing plant, repay existing debt, and fund increasing working capital requirements. Managing Director Jitendra Hegde said the firm will strive to scale the business through sustainable value creation and by providing best-in-class quality and performance. Kotak Alternate Asset Managers Ltd, which manages the fund, noted the Indian medical devices industry is at an inflection point with rising demand and government support for domestic manufacturers.

Led · Series A · Dec 2023

Monitra Health develops upBeat®, a vertically integrated remote cardiac monitoring platform that owns wearable devices, proprietary signal-acquisition technology, cloud software, analytics and clinical reporting. The company reports clinical scale—50,000+ patients monitored and over 10 billion heartbeats analyzed—and cites adoption by hospital networks including Manipal, Apollo, Aster and AIG. Monitra says revenue has grown 11x over the past four years and that patient coverage rose fivefold since its previous funding round. Its technology is supported by patents granted in the United States, Australia and India. The company positions its full-stack approach as a differentiator that drives diagnostic precision, cost advantage and scalability. Near-term plans include accelerating global certifications, expanding commercial reach within India, and building clinical and organizational capacity for global expansion.

Led · Series A · Mar 2022

Founded in 2015 by Rajneesh and Anita Bhandari, FutureCure Health develops and operates NeuroEquilibrium, an integrated platform that combines proprietary diagnostic hardware, cloud-based remote software and treatment protocols to manage vertigo and dizziness. The company partners with hospitals, ENT clinics and neurology centres to provide non-invasive vestibular diagnostics and targeted therapy. It currently runs more than 300 clinics across India and 16 other countries, having treated over 150,000 patients. FutureCure plans to scale its vertigo offering globally while expanding into other chronic lifestyle conditions such as migraine and diabetes. The firm positions its deep-tech tools as a means to bridge the shortage of specialist doctors worldwide. Recent funding underscores management’s view that globally relevant healthcare technology can be built in India. The business generates revenue from its clinical network and technology deployments, though specific financial figures beyond patient and clinic counts were not disclosed.